Proactive Investors - Run By Investors For Investors

Supreme Pharma poised to sell almost all 2016 output

If the deals turn into definite agreements, it would mean the sale of more than 250kg of dried marijuana and 70 kg of dried marijuana trim in 2016
Pictured is the firm's state-of-the-art growing facility
The group has now secured letters of intent (LOIs) with five licenced producers over the long term supply

Medical marijuana grower Supreme Pharmaceuticals Inc (CSE:SL) is on a roll.

It has now secured letters of intent (LOIs) with five licenced producers over the long term supply of marijuana.

If they turn into definite agreements, it would mean the sale of more than 250kg of dried marijuana and 70 kg of dried marijuana trim in 2016, representing pretty much all of the group subsidiary's anticipated production for 2016, the firm said.

In addition, the agreements will be renewable for successive one-year periods.

John Fowler, Supreme's president and chief executive, told investors: "These LOIs validate our B2B business model, leveraging our competitive advantage as a single-licence producer operating one of the largest, most innovative production facilities in the country.

"Our goal is to support aggregate growth in the industry by providing leading retailers with high-quality, sun-grown cannabis and today is the first step towards that goal."

Supreme is the first LP in Canada to focus exclusively on a B2B model intended to provide stable, long-term supply to retail focused LPs, it added.

The deals are conditional upon various factors, including gaining regulatory approvals, a sales licence and completion of due diligence.

Last month the group struck a strategic tie-up with  top Spanish international cannabis seed developer. Dinafem Seeds, which will supply Supreme's wholly owned subsidiary, AMMCan with seeds to be used in the group's seven-acre (342,000-square-foot) facility in Ontario.

Dinafem will also supply Supreme with exclusive continuing consulting services.

That news comes hot on the heels of the new opening of Supreme's new greenhouse.

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full SL profile View Profile

Supreme Pharmaceuticals Timeline

Related Articles

cancerous cells
March 08 2019
A series of trials underway at major cancer research hospitals are evaluating the company's flagship cancer drug Ampligen
Scientist at work
May 28 2019
CaPre, a potent form of Omega-3, has been shown to reduce triglycerides, but also lower 'bad cholesterol' levels, and raise 'good' ones
skin
April 17 2019
Driving growth was Lojuxta, used to treat a rare and life-threatening disorder that causes abnormally high levels of bad cholesterol. Its sales grew to €13.6mln, up 14.2% year-on-year
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use